📈 Jumpstart Signal Watchlist — July 20, 2026

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $11.58 is 16% below 3yr high $13.71 · ⏳ SMA200 $8.52 (current price $11.58 is above) · 💰 Market Cap $779M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); ROE 15% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.14 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (12.6%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Bioventus shares rise after Medicare reverses reimbursement cuts — Investing.com.
🤖 Bioventus shares climbed up to 13% after Medicare reversed previously issued reimbursement cuts for its non-invasive bone growth stimulators, directly improving revenue potential and pushing the stock to its highest intraday level since 2024[1].
✅ Bioventus (NASDAQ:BVS) Reaches New 12-Month High - Here's Why — MarketBeat.
🤖 The stock reached a new 12-month high with a consensus 'Buy' rating and a price target of $14.75, while Weiss Ratings reiterated a 'hold' rating, indicating strong market confidence despite the hold recommendation[5].
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Alto Ingredients, Inc. produces and distributes specialty alcohols, renewable fuels, and essential ingredients. Its products include alcohols used in items like mouthwash, cosmetics, pharmaceuticals, and cleaners, as well as fuel-grade ethanol, yeast, feed ingredients, and other corn-based co-products for food, beverage, animal feed, and industrial uses.
- 🎯 Current $5.51 is 8% below 3yr high $5.99 · ⏳ SMA200 $3.43 (current price $5.51 is above) · 💰 Market Cap $429M
- ALTO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 131% (>20%); Low LT D/E 0.31 (<1.0); PEG ratio 0.11 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 51 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Alto Ingredients (ALTO) Could Be 35% Undervalued As Russell Index Inclusion Draws Focus — Yahoo Finance.
🤖 The article argues ALTO is 35% undervalued at its recent close of $5.83 compared to a fair value of $9.00, driven by attention from its inclusion in the Russell 2000 and 3000 indexes.
✅ Why Alto Ingredients Is Earning More From Every Bushel of Corn — Yahoo Finance.
🤖 Highlights ALTO's 352.3% stock price surge over the past year and improved operational efficiency in converting corn to ethanol, outperforming the industry average growth of 3%.
❌ Alto Ingredients, Inc. (NASDAQ:ALTO) Short Interest Up 80.8% in June — MarketBeat.
🤖 Short interest surged 80.8% in June, indicating increased bearish bets against the stock, though analysts maintain a 'Hold' rating with a $10 consensus target.
🍭 Bonus (B): 0/10 — Industrial Organic Chemicals

🏢 What they do: Green Plains, Inc. (GPRE) is a leading ag-tech company that transforms annually renewable crops, primarily corn, into sustainable, high-value ingredients such as low-carbon fuel, feed proteins for pet and aquaculture markets, and corn oil for...
- 🎯 Current $16.83 is 53% below 3yr high $35.51 · ⏳ SMA200 $13.29 (current price $16.83 is above) · 💰 Market Cap $1.2B
- GPRE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 33/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 137% (>20%); Revenue growth 19% (>15%); Low LT D/E 0.48 (<1.0).
⏰ Entry (E): 11/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
- ⚠️ RSI reversing from overbought (53) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Green Plains (GPRE) Shares Skyrocket, What You Need To Know — Yahoo Finance.
🤖 UBS raised its price target on GPRE to $20 from $12 and significantly increased its Q2 and full-year 2026 EBITDA forecasts, driving shares up 9.1% to a new 52-week high despite maintaining a Neutral rating[1].
✅ UBS raises Green Plains stock price target on stronger EBITDA outlook — Investing.com.
🤖 UBS increased GPRE's price target to $20.00 from $12.00 on stronger EBITDA expectations, while the stock trades near the new target and recently reported a 940% EPS beat in Q1 2026[6].
⚪️ Hillsdale Investment Management Inc. Takes Position in Green Plains Inc (GPRE) — MarketBeat.
🤖 Hillsdale Investment Management took a new position in GPRE, though the stock maintains a consensus 'Hold' rating with an average price target of $14.29, suggesting cautious institutional interest[4].
🍭 Bonus (B): 0/10 — Industrial Organic Chemicals

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $55.53 is 3% below 3yr high $57.10 · ⏳ SMA200 $44.89 (current price $55.53 is above) · 💰 Market Cap $14.1B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (10.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 44% (>20%); ROE 43% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Exelixis, Inc. $EXEL Shares Purchased by Convergence Investment Partners LLC — MarketBeat.
🤖 Convergence Investment Partners purchased shares of $EXEL, signaling institutional confidence; the stock trades above its consensus price target of $48.80 with a market cap of $13.96 billion[2].
✅ Fifth Third Bancorp Grows Position in Exelixis, Inc. $EXEL — MarketBeat.
🤖 Fifth Third Bancorp increased its holdings in $EXEL, reflecting continued institutional support despite the stock's consensus 'Hold' rating and average target of $48.80[14].
✅ Exelixis Inc stock hits all-time high at 56.22 USD — Investing.com.
🤖 $EXEL reached an all-time high of $56.22 with a 26.7% year-to-date return, driven by analyst updates including H.C. Wainwright's Buy rating and Citizens raising its target to $55 based on Cabo script growth[7].
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 At/above 3yr high $20.97 (current $20.97) · ⏳ SMA200 $14.05 (current price $20.97 is above) · 💰 Market Cap $575M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.7%)
- 🔔 Strong above EMA50 (13.4%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Ooma, Inc. (NYSE:OOMA) Receives Consensus Recommendation of Moderate Buy from Brokerages — MarketBeat.
🤖 Six covering firms rate Ooma as a 'Moderate Buy' with four Buy and two Hold ratings, and an average 1-year price target of $22.33, signaling analyst confidence in upside potential.
✅ Hsbc Holdings PLC Buys 50114 Shares of Ooma, Inc. — MarketBeat.
🤖 HSBC Holdings purchased 50,114 shares of Ooma, reflecting institutional buying interest and reinforcing the stock's 'Moderate Buy' consensus with a $22.33 average price target.
⚪️ Ooma CEO Eric Stang sells $511,821 in company stock — Investing.com.
🤖 CEO Eric Stang sold 27,666 shares on June 24, 2026, which is typically a neutral signal; however, the article notes strong Q1 2027 earnings (EPS $0.35 vs. $0.32 estimate) and analyst price target increases to $20–$24, offsetting insider selling concerns.
⚪️ Ooma高管出售约25.13万美元公司股票 — Investing.com.
🤖 Chief Legal Officer Jenny C. Yeh sold 12,840 shares on July 1, 2026; while insider selling is neutral, the article highlights robust Q1 2027 results (EPS $0.35, revenue $81.1M) and analyst upgrades to $20–$24 targets, balancing the sentiment.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Blue Bird Corporation (BLBD) is an American manufacturer of school buses, headquartered in Fort Valley, Georgia, specializing in Type A, C, and D models powered by diesel, gasoline, propane, natural gas, and electric options.
- 🎯 At/above 3yr high $81.50 (current $81.50) · ⏳ SMA200 $59.17 (current price $81.50 is above) · 💰 Market Cap $2.6B
- BLBD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 52/60
- 🏦 Base breakout (range: 8.7%); Low drawdown (14.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; ROE 45% (>15%); Low LT D/E 0.61 (<1.0).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (5.9%)
- 🔔 Strong above EMA50 (11.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Blue Bird (NASDAQ:BLBD) Hits New 12-Month High - What's Next? — MarketBeat.
🤖 The stock hit a new 12-month high and holds a consensus 'Moderate Buy' rating with an average price target of $82.17, signaling analyst confidence in near-term upside.
✅ Blue Bird Corporation $BLBD Shares Acquired by Allspring Global Investments Holdings LLC — MarketBeat.
🤖 Allspring Global Investments acquired shares, and the stock maintains a 'Moderate Buy' consensus with 7 Buy ratings versus 2 Holds, reinforcing institutional and analyst support.
✅ Blue Bird Corp stock hits all-time high at 81.64 USD — Investing.com.
🤖 BLBD reached an all-time high of $81.64 after reporting strong Q2 FY2026 earnings ($1.00 EPS vs $0.87 expected) and $353M revenue, prompting Needham and D.A. Davidson to raise price targets to $86 while maintaining Buy ratings.
🍭 Bonus (B): 0/10 — Truck & Bus Bodies

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $31.31 is 2% below 3yr high $31.91 · ⏳ SMA200 $22.88 (current price $31.31 is above) · 💰 Market Cap $4.0B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (13.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 30% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (10.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Concentra Standout in Occupational Medicine: Analyst - Concentra Group Holdings (NYSE:CON) — Benzinga.
🤖 The article highlights that Concentra shares rose 3.26% to $30.72 and reached a new 52-week high, with analysts calling the company a standout in occupational medicine, signaling strong market confidence.
✅ Jennison Associates LLC Boosts Stake in Concentra Group Holdings Parent Inc (CON) — MarketBeat.
🤖 Jennison Associates increased its stake in Concentra, and the stock holds a 'Moderate Buy' average rating with a consensus price target of $31.40, indicating institutional support and upside potential.
⚪️ Concentra Group Holdings Parent (NYSE:CON) Director Sells $3,965,000.00 in Stock — MarketBeat.
🤖 A director sold $3.965 million in stock, which is typically neutral unless part of a larger pattern; however, the stock still maintains a 'Moderate Buy' consensus with a $30.20 price target.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Pediatrix Medical Group, Inc. (ticker: MD) is one of the nation's largest providers of physician-led prenatal, neonatal, maternal-fetal, and pediatric subspecialty services. The company partners with nearly 400 hospitals across 36 states, staffing NICUs and delivering coordinated, evidence-based care to women, babies, and children through a network of over 4,400 affiliated clinicians.
- 🎯 Current $25.71 is 6% below 3yr high $27.39 · ⏳ SMA200 $21.59 (current price $25.71 is above) · 💰 Market Cap $2.1B
- MD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 50% (>20%); ROE 20% (>15%); Low LT D/E 0.70 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 📈 RSI at 54 in healthy mid-range
- ⚠️ RSI reversing from overbought (54) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Filing: Allspring Global Investments Holdings LLC Acquires 335,733 Shares of Pediatrix Medical Group, Inc. (MD) — MarketBeat.
🤖 Allspring Global Investments Holdings LLC acquired a significant block of 335,733 shares, signaling strong institutional confidence and potential upward pressure on the stock price[2].
✅ Pediatrix Medical Group (NYSE:MD) Stock Price Up 7.1% Following Analyst Upgrade — MarketBeat.
🤖 The stock surged 7.1% immediately after an analyst upgrade, reflecting improved market sentiment and bullish expectations for the company's near-term performance[1].
⚪️ Pediatrix Medical Group Provides Second Quarter Update — Business Wire.
🤖 The company released its standard second-quarter operational update; without specific financial data or guidance in the headline, this is a routine disclosure with no immediate directional impact[5].
🍭 Bonus (B): 0/10 — Hospitals